Sputnik to combat new Covid strain India, says vaccine developer Gamaleya Center

Tribune Web Desk

Updated At : 03:12 AM Apr 29, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

Tribune News Service
New Delhi, April 28

The Sputnik V coronavirus vaccine gives enough antibodies to combat the virus’ Indian strain, the vaccine developer and director of the Gamaleya Center Alexander Gintsburg has told TASS ahead of the arrival of the first Russian shipments of the vaccine to India.

“If necessary, we will combat the Indian strain by high titers of antibodies triggered by the Sputnik V vaccine. As a rule, it generates antibodies 20, 30, 80 times as much as necessary to neutralize the biggest amount of the virus in an infected organism. Sputnik V will be effective against the Indian strain,’’ he said.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles